Chronic Myelomonocytic Leukemia-2 — Trials

Chronic Myelomonocytic Leukemia-2 — Trials · CancerIndex

Clinical trials

Registered studies

9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04734990	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	active not recruiting	Phase 1 / Phase 2	24	M.D. Anderson Cancer CenterOTHER	1	Sep 18, 2026	clinicaltrials
NCT01522976	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	active not recruiting	Phase 2	282	National Cancer Institute (NCI)NIH	2	Sep 9, 2026